Combination Therapy
Approved for: SCLC
Durvalumab (Imfinzi) is a FDA-approved treatment for small cell lung cancer (SCLC) in adults. It is used with etoposide phosphate and either carboplatin or cisplatin as first-line therapy in adults with extensive-stage disease.
